In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.
|Articles|October 26, 2009
Rho Celebrates 25th Anniversary
Advertisement
Chapel Hill, NC
October 24, 2009 marked the 25th Anniversary for
During the past 25 years, Rho has acquired a strong commercial and federal customer base because of its customer service and scientific expertise. Consulting to the FDA, rescuing poorly executed pivotal trials, authoring and coauthoring 252 articles, 89 presentations, and 82 abstracts are
among of Rho’s accomplishments.
Rho contributes to the success of pharmaceutical, medical device, and biotechnology studies in a range of therapeutic areas.
Advertisement
Related to this article
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How a Platform Approach Can Scale AI’s Impact in Life Sciences
2
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
3
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
4
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
5